NEX-I Overview
- Year Founded
-
2021
- Status
-
Public
- Employees
-
36
- Stock Symbol
-
493410
NEX-I General Information
Description
Developer of next-generation Immunotherapeutics designed to induce cancer cells to become refractory to the current treatment. The company's platform designs assessment tools to evaluate the efficacy of cancer immunotherapy and aims to change the current standard of care in anti-cancer therapies to deliver new clinical value, enabling healthcare providers to improve patients' quality of life.
Contact Information
Website
www.nex-i.co.krCorporate Office
- A-1611, 16F, 201 Songpa-daero
- Songpa-gu
- Seoul
- South Korea
Corporate Office
- A-1611, 16F, 201 Songpa-daero
- Songpa-gu
- Seoul
- South Korea
NEX-I Financials Summary
As of 31-Dec-2025, NEX-I has a trailing 12-month revenue of $3.58M.
|
In Thousands, USD |
TTM 31-Dec-2025 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| Revenue | 3,584 | 3,584 | 10,334 | |
| Total Assets | 7,118 | |||
| Total Debt | 0 |
NEX-I Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
NEX-I Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
NEX-I Patents
NEX-I Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026168812-A1 | Antibody specifically binding to tctp and use thereof | Pending | 05-Feb-2025 | ||
| EP-4683946-A1 | Api5 epitope and antibody specifically binding to the same | Pending | 21-Mar-2023 | ||
| EP-4683946-A4 | Api5 epitope and antibody specifically binding to the same | Pending | 21-Mar-2023 | ||
| WO-2024196179-A1 | Api5 epitope and antibody specifically binding to the same | Inactive | 21-Mar-2023 | ||
| JP-2026511516-A | Api5 epitope and antibody that specifically binds to it | Pending | 21-Mar-2023 | C07K16/30 |
NEX-I Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
NEX-I Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
NEX-I FAQs
-
When was NEX-I founded?
NEX-I was founded in 2021.
-
Where is NEX-I headquartered?
NEX-I is headquartered in Seoul, South Korea.
-
What is the size of NEX-I?
NEX-I has 36 total employees.
-
What industry is NEX-I in?
NEX-I’s primary industry is Drug Discovery.
-
Is NEX-I a private or public company?
NEX-I is a Public company.
-
What is NEX-I’s stock symbol?
The ticker symbol for NEX-I is 493410.
-
What is NEX-I’s current revenue?
The trailing twelve month revenue for NEX-I is $3.58M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
